Physician profile
William Kelly
NPI 1376781443
$715.88
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $188.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $156.10 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $99.34 | 2019-2020 | |
| Genentech USA, INC. | $64.71 | 2019-2020 | |
| Amgen INC. | $58.09 | 2020 | |
| Celgene Corporation | $38.14 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $35.96 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $35.42 | 2019 | |
| Pfizer INC. | $29.08 | 2019 | |
| Lilly USA, LLC | $25.41 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.82 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.08 | 2019 | |
| Alexion Pharmaceuticals, INC. | $21.32 | 2019 | |
| Btg International INC. | $20.65 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.10 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $17.75 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $16.76 | 2019 | |
| Rigel Pharmaceuticals, INC. | $16.71 | 2019 | |
| Merck Sharp & Dohme LLC | $13.44 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.